Not recruiting
Multiple sclerosis
Not recruitingStudy on the Safety and Effectiveness of TolDec and Immunotherapy for Patients with Relapsing-Remitting Multiple Sclerosis
InvestigationalNo placebo
Study on the Safety and Effectiveness of TolDec and Immunotherapy for Patients with Relapsing-Remitting Multiple Sclerosis
InvestigationalNo placebo
- Disease:Multiple sclerosis
- Substances:Autologous tolerogenic dendritic cells
Countries:
Spain
Spain- Participants:18–64 years
- Substances:Autologous tolerogenic dendritic cells
